Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07664553 · ClinicalTrials.gov registry record · Phase 3

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

A Phase 3 study, sponsored by AstraZeneca.

Not yet
Registry status
Phase 3
Development phase
600
Enrollment target

NCT07664553: Clinical Trial Phase 3 study, sponsored by AstraZeneca.

NCT07664553 is a Phase 3 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07664553, a Phase 3 study, has not yet begun recruiting, sponsored by AstraZeneca.

NOT YET RECRUITING
Registry status
Phase 3
Development phase
600 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

Primary Outcome

Summary statistics

Interventions

  • DRUG Placebo
  • DRUG Elecoglipron

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2026-07-06
Est. Completion 2028-05-23
Phase Phase 3
AstraZeneca

1,285 total trials

What is known before NCT07664553 opens enrollment

NCT07664553 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07664553 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07664553 about?

NCT07664553 is a clinical study titled "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin". The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

What is the current status of trial NCT07664553?

This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2026-07-06. Estimated completion is 2028-05-23.

What interventions are being tested in trial NCT07664553?

The interventions under investigation include: Placebo (DRUG), Elecoglipron (DRUG).

Who is sponsoring clinical trial NCT07664553?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07664553's enrollment target sits among peer trials

600 608th of 2000 higher than 1,363 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07664553, the US trial registry maintained by the National Library of Medicine. NCT07664553 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.